Blue Nevi, Combined Nevi, and Deep Penetrating Nevi

01Common blue nevus presents as a small, well-circumscribed steel-blue or blue-grey papule, classically on the dorsum of the hands or feet, scalp, or buttocks. Histopathologically, dendritic melanocytes lie among thick collagen bundles in the deep dermis, separated from the epidermis by a Grenz zone. Dermoscopy shows a structureless homogeneous blue color without network, dots, globules, or vessels. Sharp borders, uniform color, and stability over years are the hallmarks of benignity. Hypochromic (lightly pigmented) blue nevi exist and appear pale blue or white-blue; pigment loss is more frequent on the limbs.

02Cellular blue nevus is a larger, deeper variant, typically 1-3 cm, often on the buttocks, sacrum, scalp, or distal extremities. Clinically, it presents as a firm blue or blue-grey nodule. Histopathologically, biphasic (cellular and conventional) architecture with islands of plump spindle cells in a dendritic background extends deep into the dermis or subcutis. Dermoscopy shows homogeneous blue or blue-grey color sometimes with a peripheral pale brown rim. Cellular blue nevi are benign but rare malignant transformation (malignant blue nevus, also called blue-nevus-like melanoma) is reported, presenting with rapid growth, ulceration, asymmetry, and color heterogeneity. Sentinel lymph node biopsy positivity has been reported in cellular blue nevus without metastatic disease, complicating staging.

03Plaque-type blue nevus presents as a segmental or zosteriform blue patch or plaque, often congenital or appearing in childhood, with a preference for the trunk, scalp, and buttocks. The histopathologic correlate is widespread dermal dendritic melanocytes in a flat distribution. Dermoscopy shows diffuse blue homogeneous color with sometimes faint network at the periphery if a junctional component coexists. Plaque-type blue nevus carries a low but reported risk of malignant transformation and warrants periodic clinical and dermoscopic follow-up.

04Epithelioid blue nevus is a distinct entity associated with Carney complex (autosomal dominant syndrome with cardiac myxoma, lentigines, and endocrine overactivity). Multiple epithelioid blue nevi at unusual sites in a young patient with cutaneous lentigines or family history of cardiac myxoma should prompt PRKAR1A genetic testing. Histopathology shows heavily pigmented epithelioid melanocytes intermixed with spindle dendritic cells. Dermoscopy is non-specific structureless blue.

05Deep penetrating nevus (also called plexiform spindle cell nevus) is a combined morphologic entity with features bridging blue nevus, Spitz nevus, and deep extension. Clinically, it presents as a small (3-9 mm) deeply pigmented blue-black or dark brown papule, often on the head, neck, or upper trunk. Histopathologically, wedge-shaped extension of plump spindle and epithelioid melanocytes into the deep dermis is characteristic, with frequent pigment incontinence. Dermoscopy shows homogeneous blue-black color sometimes with peripheral brown halo, and the lesion is often confused with nodular melanoma at first glance. Molecularly, GNAQ, GNA11, and CYSLTR2 mutations are recurrent, overlapping with blue nevus genetics. Recent reports also describe BAP-1 loss in some deep penetrating nevi.

06Combined nevus is defined by the juxtaposition of two morphologically distinct melanocytic populations within a single lesion (most commonly a common blue nevus component within a conventional acquired nevus, but combinations of Spitz with conventional, blue with Spitz, and other pairings exist). Dermoscopically, combined nevi show two distinct patterns side by side (e.g., reticular plus homogeneous blue, or globular plus blue) often with a sharp boundary. The lesion can mimic multicomponent melanoma, but symmetric distribution of the two components and individual blandness of each support combined nevus. Asymmetric or growing combined morphology should be excised.

07Malignant blue nevus and blue-nevus-like melanoma represent the malignant end of the spectrum. They are exceedingly rare but aggressive, presenting as growing blue or blue-black nodules, often on the scalp, with ulceration and asymmetry. Histopathology shows nuclear atypia, mitoses, necrosis, and asymmetric architecture; molecular workup may reveal GNAQ or GNA11 mutations plus additional progression events (BAP-1 loss, monosomy 3, or other chromosomal aberrations similar to uveal melanoma). Dermoscopy may show heterogeneous blue color, irregular borders, and atypical vessels but the lesion is often overdiagnosed as cellular blue nevus until histopathology resolves.

08Dermoscopic mimics of blue nevus include Mongolian spot (large dermal melanocytosis on the lumbosacral area of infants, fading by adolescence), nevus of Ota and Ito (periocular and shoulder dermal melanocytosis, persistent through adulthood), tattoos (especially decorative tattoos with blue ink), drug-induced pigmentation (minocycline, antimalarials, amiodarone, gold salts), ochronosis (alkaptonuria or hydroquinone-induced), blue-grey lichen planus pigmentosus, fixed drug eruption (resolved phase), and nodular melanoma metastasis. The key discriminator is structureless blue color, sharp border, and stability for blue nevus versus context-dependent features for the mimics.

09Apocrine and tubular adenoma / RT (rare tumors) and dermatofibroma occasionally enter the blue nevus differential when they show predominant blue-black pigmentation. The blue-grey peppering of regression structures in melanoma can mimic blue homogeneous color in small lesions. Conscious application of the rule that any blue lesion that grows, ulcerates, or develops asymmetric features is excised resolves most edge cases.

10Molecular biology has revealed that GNAQ Q209 and GNA11 Q209 mutations are recurrent in common blue nevus, cellular blue nevus, and deep penetrating nevus. The same GNAQ R183Q mutation underlies port-wine stains and Sturge-Weber syndrome, illustrating mutation site specificity. CYSLTR2 mutations have been described in a subset of blue nevus family lesions. In malignant blue nevus and related blue-nevus-like melanoma, additional events (BAP-1 loss, EIF1AX mutations, SF3B1 mutations) parallel uveal melanoma progression and may confer therapeutic implications including MEK inhibitor sensitivity in select cases.